Lingamneni Anila
Known title: EVP, Chief Technology OfficerCIK: 0001808414
Associated companies
Transaction History
| HAE | ▼ Sell | Open Market | 79 | $7K | 7/12/2024 | View on chart |
| HAE | ▼ Sell | Open Market | 2,136 | $192K | 7/11/2024 | View on chart |
| HAE | ▲ Buy | Grant | 14,140 | $0 | 5/28/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 5,279 | $505K | 5/28/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 349 | $33K | 5/17/2024 | View on chart |
| HAE | ▲ Buy | Grant | 3,394 | — | 5/17/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 318 | $30K | 5/16/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 337 | $33K | 5/15/2024 | View on chart |
| HAE | ▼ Sell | Open Market | 2,305 | $219K | 5/6/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 184 | $16K | 4/15/2024 | View on chart |
| HAE | ▼ Sell | Open Market | 2,305 | $207K | 9/11/2023 | View on chart |
| HAE | ▼ Sell | Open Market | 2,304 | $192K | 5/30/2023 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 1,385 | $115K | 5/18/2023 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 318 | $28K | 5/16/2023 | View on chart |
| HAE | ▲ Buy | Grant | 3,364 | — | 5/15/2023 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 176 | $15K | 4/14/2023 | View on chart |
| HAE | ▼ Sell | Open Market | 1,384 | $82K | 5/19/2022 | View on chart |
| HAE | ▲ Buy | Grant | 4,340 | — | 5/16/2022 | View on chart |
| HAE | ▼ Sell | Open Market | 189 | $11K | 4/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump
Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump. Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.